Mesoblast (NASDAQ:MESO) Shares Gap Up to $5.21

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $5.21, but opened at $5.39. Mesoblast shares last traded at $5.48, with a volume of 106,631 shares traded.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MESO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Friday, January 12th. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $13.67.

Mesoblast Stock Performance

The business has a 50 day moving average of $3.46 and a 200 day moving average of $2.64.

Hedge Funds Weigh In On Mesoblast

A hedge fund recently raised its stake in Mesoblast stock. Lazari Capital Management Inc. boosted its position in shares of Mesoblast Limited (NASDAQ:MESO) by 9.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 94,034 shares of the company’s stock after buying an additional 8,000 shares during the period. Lazari Capital Management Inc. owned approximately 0.06% of Mesoblast worth $116,000 as of its most recent SEC filing. 1.43% of the stock is owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.